Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) have earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $55.40.

Separately, Oppenheimer reduced their target price on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a report on Friday, August 14th.

Insider Transactions at Pelthos Therapeutics

In other Pelthos Therapeutics news, Director Todd C. Davis acquired 35,948 shares of Pelthos Therapeutics stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the purchase, the director owned 75,834 shares in the company, valued at approximately $2,109,701.88. The trade was a 90.13% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders sold 1,638 shares of company stock valued at $43,107. 16.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Pelthos Therapeutics

A number of hedge funds have recently made changes to their positions in PTHS. Geode Capital Management LLC boosted its holdings in shares of Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after purchasing an additional 3,295 shares during the period. Knott David M Jr grew its position in Pelthos Therapeutics by 215.5% during the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock valued at $598,000 after purchasing an additional 13,169 shares in the last quarter. Persistent Asset Partners Ltd increased its stake in Pelthos Therapeutics by 150.0% in the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after buying an additional 3,604 shares during the period. Diadema Partners LP lifted its position in Pelthos Therapeutics by 138.1% in the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after buying an additional 14,502 shares in the last quarter. Finally, Cantor Fitzgerald L. P. purchased a new stake in Pelthos Therapeutics in the 4th quarter worth approximately $1,085,000. 77.96% of the stock is owned by hedge funds and other institutional investors.

Pelthos Therapeutics Stock Performance

Pelthos Therapeutics stock opened at $24.35 on Friday. The firm’s 50 day simple moving average is $26.71 and its 200-day simple moving average is $25.36. The company has a market cap of $93.26 million, a P/E ratio of -1.11 and a beta of 3.01. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31. Pelthos Therapeutics has a fifty-two week low of $18.19 and a fifty-two week high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. The firm had revenue of $15.60 million during the quarter. As a group, equities research analysts predict that Pelthos Therapeutics will post -15.22 EPS for the current year.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).